Page last updated: 2024-12-08

2,3-diaminophenazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-diaminophenazine: product form horseradish peroxidase catalyzed oxidation of o-phenylenediamine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID410099
CHEMBL ID274921
SCHEMBL ID188079
MeSH IDM0153449

Synonyms (48)

Synonym
unii-0b20h27u1y
0b20h27u1y ,
BB 0260350
EU-0099915
einecs 211-512-0
brn 0014422
phenazine-2,3-diyldiamine
ccris 3576
2,3-diaminophenazine
phenazine, 2,3-diamino-
CBDIVE_002746
CBDIVE_005143
STK095585
phenazine-2,3-diamine
nsc26432
2,3-phenazinediamine
2,3-diaminophenazine, 90%
smr000424784
MLS001044416 ,
AKOS000112882
VU0151812-2
CHEMBL274921
F0850-6510
655-86-7
HMS2800F16
FT-0609762
PS-5430
SCHEMBL188079
2,3-diaminophenazine [mi]
diaminophenazine, 2,3-
mfcd00160693
VZPGINJWPPHRLS-UHFFFAOYSA-N
2,3-phenazinediamine #
bdbm51287
cid_410099
(3-aminophenazin-2-yl)amine
AC-31133
Z56757698
3,5-dihydro-2-amino-3-iminophenazin
BCP08073
F15496
DTXSID40984097
Q27236559
A847172
EN300-235752
CS-0033385
HY-W020086
D4492
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency0.44560.140911.194039.8107AID2451
LuciferasePhotinus pyralis (common eastern firefly)Potency19.01150.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency22.38720.01846.806014.1254AID624417
WRNHomo sapiens (human)Potency3.54810.168331.2583100.0000AID651768
phosphopantetheinyl transferaseBacillus subtilisPotency1.99530.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency18.35640.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency5.44570.180013.557439.8107AID1460; AID1468
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency4.46680.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.25890.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency5.01190.01262.451825.0177AID485313
importin subunit beta-1 isoform 1Homo sapiens (human)Potency31.62285.804836.130665.1308AID540253
DNA polymerase betaHomo sapiens (human)Potency3.98110.022421.010289.1251AID485314
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency15.84890.65619.452025.1189AID463254
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency6.70160.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency31.62285.804836.130665.1308AID540253
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency35.48130.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency67.45550.425612.059128.1838AID504891
tumor susceptibility gene 101 proteinHomo sapiens (human)Potency33.90210.129810.833132.6090AID493005; AID651600
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency31.62285.804816.996225.9290AID540253
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency3.54810.075215.225339.8107AID485360
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Apoptotic peptidase activating factor 1Homo sapiens (human)IC50 (µMol)100.00000.037518.623253.2000AID588524; AID588538
RevHuman immunodeficiency virus 1IC50 (µMol)9.52908.31208.92059.5290AID434976
Female germline-specific tumor suppressor gld-1Caenorhabditis elegansIC50 (µMol)4.97401.47104.96148.4010AID2802
3-oxo-5-alpha-steroid 4-dehydrogenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)9.86000.00427.468021.1000AID2073
3-oxo-5-alpha-steroid 4-dehydrogenase 2Rattus norvegicus (Norway rat)IC50 (µMol)9.86000.00037.329421.1000AID2073
BZLF2Human herpesvirus 4 type 2 (Epstein-Barr virus type 2)IC50 (µMol)0.42000.42004.434216.2300AID1419
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1191319Antiproliferative activity against human A549 cells2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
AID79769Cytotoxic concentration of compound HC40 cells determined by using MTT assay2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules.
AID1191320Antiproliferative activity against human HCT116 cells2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
AID1191321Inhibition of tyrosine kinase in human A549 cells at IC50 after 24 hrs by ELISA relative to control2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
AID232668Ratio of inhibitory concentration against Hepatitis C Viral IRES in HC40 cells to that of HCF cells was determined2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules.
AID79770Anti-Hepatitis C Viral IRES activity of compound by measured as Fluci signal in HC40 cells2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules.
AID1191322Inhibition of tyrosine kinase in human HCT116 cells at IC50 after 24 hrs by ELISA relative to control2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthesis and antiproliferative activity of novel polynuclear heterocyclic compounds derived from 2,3-diaminophenazine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.44)18.7374
1990's7 (17.07)18.2507
2000's11 (26.83)29.6817
2010's18 (43.90)24.3611
2020's4 (9.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.85 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index5.43 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]